Skip to content

Effect of the Bioheat Patch on Pain Following the HyFoSy Procedure

Effect of the Bioheat Patch on Pain Following the HyFoSy Procedure

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07081971
Acronym
B-HyP
Enrollment
80
Registered
2025-07-24
Start date
2025-08-01
Completion date
2025-12-30
Last updated
2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic Procedures, Infertility, Pain Management, Pelvic Pain

Brief summary

This randomized controlled trial (RCT) evaluates the efficacy of Bioheat thermal patches in reducing post-procedural pain following Hysterosalpingo Foam Sonography (HyFoSy). HyFoSy is a common ultrasound-based diagnostic procedure to assess tubal patency and uterine cavity structure in women undergoing fertility workup. While generally less painful than HSG, many patients still report moderate to severe cramping and discomfort during and after the test. Thermal therapy has demonstrated effectiveness in reducing musculoskeletal and gynecological pain. Bioheat patches, approved by the Israeli Ministry of Health for menstrual pain relief, emit safe, low-grade heat (approximately 37-38°C) and may provide a non-invasive pain management strategy post-HyFoSy. Participants (n=80) will be women aged 20-45 undergoing HyFoSy. They will be randomly assigned to either the Bioheat intervention group or a placebo patch group, applied externally to the lower abdomen. The heat-producing patch contains iron and other safe materials that react with oxygen to emit continuous heat without electricity. Infrared radiation from the patch components may also promote local vasodilation and muscle relaxation. Pain assessment will use the validated Visual Analog Scale (VAS), collected post-procedure via follow-up SMS and phone contact. The study aims to quantify reduction in perceived pain, and potentially improve patient satisfaction with HyFoSy. Safety has been pre-established, with no reported adverse skin effects when used as instructed. Study duration is six months, following ethics approval at the OB-GYN ultrasound department of Shamir Medical Center.

Interventions

OTHERBioheat Patch

Bioheat Patch for pain relif

OTHERPlacebo Patch

placebo Patch

Sponsors

Assaf-Harofeh Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

Women aged 18-45 scheduled for HyFoSy No dermatologic conditions at the patch site No allergies to patch ingredients, or heat No active pelvic infections

Exclusion criteria

Active genital infection Skin issues in lower abdomen Sensitivity to heat Any medical condition preventing local heat use

Design outcomes

Primary

MeasureTime frameDescription
Change in pain intensity measured by Visual Analog Scale (VAS)Up to 6 hours post-procedurePain will be assessed using the VAS (range: 0-10; 0 = no pain, 10 = worst imaginable pain). Participants will self-report their score via questionnaire within 6 hours after the procedure.

Contacts

Primary ContactProf. Yaakov Melcer Prof. Yaakov Melcer Principal Investigator shamir Medical, MD
ymeltcer@gmail.com+972547781821

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026